CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases 2021

Biocon  /  News – Posts  /  Press Releases  /  Press Releases 2021

Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents

  • Posted by: BIOCON

Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval

  • Posted by: BIOCON

Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East

  • Posted by: BIOCON

Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index

  • Posted by: BIOCON

Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club

  • Posted by: BIOCON

Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection

  • Posted by: BIOCON

Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day

  • Posted by: BIOCON

Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies

  • Posted by: BIOCON

Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr;

  • Posted by: BIOCON

Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US

  • Posted by: BIOCON
Share
Previous Next
Close
Test Caption
Test Description goes like this